A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
Trial details
- Registry ID
- NCT05002127
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)NCT05002127 | ALX Oncology Inc. | Phase 2, Phase 3 | Completed | 2024-05-24Actual |
| ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerNCT07007559 | ALX Oncology Inc. | Phase 2 | Recruiting | 2027-12Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |